Infectious Diseases

This week, HHS Secretary Robert F. Kennedy Jr signed the ACIP's recommendation to remove the mercury-based preservative from all influenza vaccines.

Nirsevimab reduced RSV-related illness by up to 98% and lowered the amount of hospitalizations and health care use among healthy term infants in a real-world study.

In this episode of Infectious Insights, our host Tina Tan, MD, is joined by general pediatrician Candice Jones, MD, to discuss an unprecedented vaccine season.

Lori Handy, MD, MSCE, emphasizes the role of school entry as a critical time for ensuring children are caught up on routine vaccinations.

Discover the latest in pediatric infectious diseases with Infectious Insights, a new podcast series hosted by expert Tina Tan, MD, FIDSA, FPIDS, FAAP.

Early antibiotic exposure disrupts infant immune development by altering gut microbiota, highlighting inosine's potential as a therapeutic target for immune restoration.

A newly-published study identified specific groups of higher-risk children that could benefit most from monoclonal antibodies.

A week into July 2025, the total reported cases in the United States have surpassed the peak of 1274 cases recorded for all 2019.

Six medical societies, including the American Academy of Pediatrics, are suing the HHS and its Secretary to "defend vaccine policy."

Mycoplasma pneumoniae caused 1 in 2 pediatric pneumonia hospitalizations in 2024, with sharp increases seen across all age groups, according to a recent CDC MMWR report.

The final recommendation sign off decision will go to HHS secretary Robert F. Kennedy Jr.

The American Academy of Pediatrics will continue to hold its own childhood vaccine schedule, as it has since the 1930s.

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, shares her thoughts on how PNPs can implement evidence-based strategies to encourage parents to vaccinate their children.

Octavio Ramilo, MD, joins us once again to discuss potential benefits of RSV vaccination beyond disease prevention and to explain how to speak with patients about vaccines and uptake.

In this video, the last in a 3-part series, panelists discuss future directions in the field and the importance of multispecialty collaboration.

In this video, part 2 in a 3-part series, panelists discuss clesrovimab's recent approval and gaps in clinician education.

In this video, the first in a 3-part series, panelists discuss recent advancements in RSV management.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Glecaprevir/pibrentasvir was a "highly efficacious treatment for people with acute HCV," with 96.2% of patients analyzed having sustained virological response 12 weeks post-treatment.

Aaron Milstone, MD, MHS, emphasizes the role of pediatricians in educating families on infection prevention practices for infants in the NICU, where Staphylococcus aureus remains a serious threat.

Ramilo, a clesrovimab clinical trial investigator, breaks down the recent FDA approval for the newest monoclonal antibody to protect against RSV disease in infants.

The BLA for clesrovimab was based on results demonstrated in the phase 2b/3 CLEVER trial among healthy pre-term and full-term infants.

Aaron Milstone, MD, emphasizes the need for better recognition and prevention of Staphylococcus aureus infections in neonatal intensive care units.

Six-month results from the phase 2 VLA1553-221 trial aligned with initial data and demonstrated immune response at day 180 among patients aged 1 to 11 years.

Aaron Milstone, MD, explains that very low birth weight infants remain disproportionately affected by deadly Staph aureus infections in NICUs.